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Pain Exposure Physical Therapy 
versus conventional treatment in 
complex regional pain syndrome 
type 1—a cost-effectiveness  
analysis alongside a randomized 
controlled trial
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Abstract
Objective: To analyze cost-effectiveness of Pain Exposure Physical Therapy compared to conventional 
treatment alongside a randomized controlled trial (NCT00817128) in patients with complex regional pain 
syndrome type 1, where no clinical difference was shown between the two groups in an intention-to-treat 
analysis.
Design: Randomized controlled trial with 9 months follow-up.
Setting: Patients were recruited from hospitals and general practitioners in the region around a university 
hospital.
Subjects: A total of 56 patients, 45 (80.4%) female, were randomized. About 4 patients in the intervention 
and 11 patients in the conventional group switched groups. The mean (SD) age was 44.3 (16.6) years, and 
in 37 (66.1%) patients, the upper extremity was affected.
Interventions: Patients received either Pain Exposure Physical Therapy (maximum of five sessions), or 
conventional treatment conforming with the Dutch multidisciplinary guideline.
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Main measures: For the economic evaluation difference between the groups in health-related quality 
of life (quality-adjusted life years (QALYs)), and the clinical outcomes Impairment level Sum Score—
Restricted Version and Pain Disability was determined based on the intention-to-treat analysis as well 
as differences in both healthcare-related costs and travel expenses. Cost-effectiveness planes were 
constructed using bootstrapping to compare effects and costs.
Results: No significant effects were found for QALYs (mean difference = −0.02; 95% confidence interval 
(CI) −0.10 to 0.04) and clinical outcomes. A cost minimization analysis showed a significant difference 
in costs between groups. The conventional treatment was 64% more expensive than the Pain Exposure 
Physical Therapy.
Conclusion: This economic analysis shows that Pain Exposure Physical Therapy compared to conventional 
treatment is cost-effective.
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Introduction
A randomized controlled study published in 2015 
found no clinical difference between two different 
types of treatment for people with complex regional 
pain syndrome type 1,1 but we did observe a differ-
ence in the use of healthcare resources. Because 
currently there is no effective management availa-
ble, less economic costs with comparable outcomes 
are relevant and interesting.
Complex regional pain syndrome type 1 is a 
debilitating condition that usually develops follow-
ing injury, but can also arise spontaneously.2 The 
disorder is characterized by pain and sensory, auto-
nomic, motor, and/or trophic changes.3 There is 
emerging evidence that pain-related fear and avoid-
ance behavior can lead to disease deterioration and 
the development of chronic pain-related disability.4,5 
Despite elaborate research, treatment of complex 
regional pain syndrome type 1 can still be disap-
pointing and there is a need for more high-quality 
evidence for the effectiveness of most therapies.6,7
In the present randomized controlled trial, we 
compared a Pain Exposure Physical Therapy 
approach to the Dutch conventional guideline-
based treatment in patients with complex regional 
pain syndrome type 1.1 The guideline includes 
pharmacological interventions with various drugs 
and intensive pain-contingent physical therapy 
sometimes taking a few months or even years. Key 
element of the Pain Exposure Physical Therapy 
intervention is to stimulate the use of the affected 
extremity while simultaneously ignoring the 
pain.1,8 Although we found no difference in clinical 
effect between both interventions we expected that 
early and forced use in daily life, without the use of 
medication, would lead to lower costs.1,9,10 Pain 
Exposure Physical Therapy follows a time-contin-
gent treatment scheme with a maximum of five 
treatment sessions.
Complex regional pain syndrome type 1 is a 
very costly disorder. Annual costs for chronic 
regional pain syndrome type 1 in the Netherlands 
have been estimated between €32.5 million and 
€47.3 million, including medical costs as well as 
nonmedical costs and costs of lost productivity.11,12 
With this particular study, we investigated the 
potential cost-effectiveness of Pain Exposure 
Physical Therapy versus conventional treatment.8
Methods
Study design and participants
This economic evaluation was conducted along-
side a randomized controlled trial with 9 months 
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follow-up.1,8 This trial was prospectively registered 
at http://www.clinicaltrials.gov, NCT00817128, 
and at http://www.trialregister.nl, NTR 2090. The 
study was approved by the regional ethical com-
mittee (ABR no: NL24762.091.08).
The design of the trial and the primary clinical 
results are published elsewhere.1
The cost data were collected after completion of 
the trial. Patients were recruited from hospitals and 
general practitioners in the region of the Radboud 
University Medical Center, in Nijmegen, The 
Netherlands. Recruitment took place from January 
2009 until June 2011. Patients were included if they 
fulfilled the diagnostic criteria for complex regional 
pain syndrome type 1 as proposed by Harden 
et al.,13 age between 18 and 80 years, and first 
assessment between 3 and 24 months after the incit-
ing event. Patients were excluded if they had com-
plex regional pain syndrome type 1 in more than 
one extremity, a relapse of complex regional pain 
syndrome type 1, impairments of the contralateral 
extremity or prior sympathectomy of the affected 
extremity, or when they were pregnant or lactating. 
We used the Consolidated Health Economic 
Evaluation Reporting Standards Checklist to report 
the economic analysis.14
Interventions
Patients were randomly allocated in a 1:1 ratio to 
receive either Pain Exposure Physical Therapy 
consisting of a maximum of five physical therapy 
sessions or conventional guideline-based treat-
ment. More details on the interventions can be 
found elsewhere.1,9,10,15
Outcome measures
Costs. Cost categories were defined as direct costs, 
which were healthcare-related costs and travel 
expenses. These categories included physical ther-
apy consultations, both as part of the allocated 
intervention and as outpatient physical therapy 
consultations, general practitioners consultations, 
consultations of the Pain Treatment Center at our 
university hospital, consultations of other health-
care providers (e.g. podiatrists, anesthesiologists 
for Transcutaneous Electrical Nerve Stimulation), 
medication costs, and travel expenses. Only the 
costs directly related to the treatment of complex 
regional pain syndrome type 1 were incorporated 
in the analyses. Volumes of care were measured 
using the electronic patient record system and 
patients’ medical records. Associated costs were 
verified with individual information from health 
insurance companies, after patients had given writ-
ten consent for this. Cost prices were determined 
using standard unit cost prices according to the 
Dutch guidelines for costing research and the cur-
rency was euro.16 Travel expenses were calculated 
by multiplying the total traveled distance from 
home to the healthcare provider with the standard 
travel expense rate.
Health-related quality of life. Health-related quality 
of life was measured with the EuroQol-5D-3 L 
(EQ-5D),17 a validated so-called health-related 
quality-of-life instrument.18 This instrument is 
available in a validated Dutch translation.19 The 
EQ-5D is a generic health-related quality-of-life 
instrument comprising five domains: mobility, 
self-care, usual activities, pain/discomfort, and 
anxiety/depression. The EQ-5D index is obtained 
by applying predetermined weights to the five 
domains. This index gives a societal-based global 
quantification of the patient’s health status on a 
scale ranging from 0 (death) to 1 (perfect health). 
Patients were asked to rate their overall health-
related quality of life on a visual analog scale con-
sisting of a vertical line ranging from 0 (worst 
imaginable health status) to 100 (best imaginable).
We converted the EQ-5D score into a utility 
score using the Dutch algorithm. The utility score 
has a maximum of 1, indicating optimal health. A 
utility score of 0 equals death, but the score can 
also be negative, as some conditions are thought to 
be worse than death. By multiplying the utility 
score with the amount of time in which the score is 
applicable and then aggregate these scores over the 
relevant timeframe (trapezium method), quality-
adjusted life years (QALYs) can be computed.20
Clinical measurements. We measured the severity of 
complex regional pain syndrome type 1 using the 
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Impairment level Sum Score—Restricted Version 
(range of 4–40, with a lower score indicating less 
impairment), which consisted of three measure-
ment parameters focusing on typical signs and 
symptoms (pain, active range of motion, and tem-
perature).21 Pain Disability was measured using the 
Pain Disability Index. This is a widely used ques-
tionnaire for measuring disability related to muscu-
loskeletal pain. It is a seven-item questionnaire 
with a score ranging from 0 to 70 points that 
assesses to which extent daily activities are dis-
rupted by pain. A lower score indicates less 
disability.22
Data analyses
We analyzed the data according to the intention-to-
treat principle. Differences in costs between treat-
ment groups were calculated using a generalized 
linear model with a log link function and with a 
gamma distribution to account for skewness in the 
data. For analyzing health-related quality of life we 
used univariate analysis of covariance, with treat-
ment as fixed factor and EQ-5D utility at baseline 
as covariate. The analyses of the clinical outcomes 
have been described previously.1 If a significant 
difference in EQ-5D score is found the “efficiency” 
decision rule will follow the net monetary benefit 
approach where the effect difference in QALYs 
(according to the EQ-5D difference score) will be 
multiplied with an appropriate willingness to pay 
for a QALY (as used in the Netherlands). Then the 
cost difference is subtracted from this score, lead-
ing to an incremental net monetary benefit (iNMB), 
and the result of this iNMB should be larger than 
zero for being efficient. If no significant difference 
in EQ-5D is found we use a cost minimization 
analysis for the criterion “efficiency.” Bootstrapped 
Incremental Cost-effectiveness Ratios are pre-
sented for health-related quality of life, clinical 
outcomes, and costs.
Results
Participants
A total of 56 patients, mean age 44.3 years (SD, 
16.6), 45 female (80.4%), were included in the trial 
and randomized to either Pain Exposure Physical 
Therapy or conventional treatment, 4 patients in 
the Pain Exposure Physical Therapy group, and 11 
patients in the conventional treatment group opted 
out of their assigned treatment and switched 
groups. These patients were analyzed according to 
their randomization, following the intention-to-
treat principle and were excluded from the per-pro-
tocol analysis (Figure 1).
Health-related quality of life and clinical 
outcomes
Data on health-related quality of life were available 
for 42 patients (23 in the Pain Exposure Physical 
Therapy group and 19 in the conventional treat-
ment group). The EQ-5D increased by 0.23 points 
in the Pain Exposure Physical Therapy group and 
0.27 points in the conventional treatment group 
after 9 months (Table 1). The difference in mean 
QALY was −0.02 (95% confidence interval (CI) 
−0.10 to 0.04), which is not statistically significant. 
The non-significant results for the clinical out-
comes Impairment level Sum Score and Pain 
Disability have been presented elsewhere.1
Costs and health services used
The cost minimization analysis (as there were no 
significant differences in EQ-5D results and clini-
cal outcomes) showed that conventional treatment 
was 1.64 (95% CI 1.05 to 2.56) times more expen-
sive than Pain Exposure Physical Therapy. Thus, 
the mean cost of conventional treatment was €2783 
or 64% greater compared to the Pain Exposure 
Physical Therapy group cost of €1695. The mean 
costs per cost category are shown in Table 2 and in 
Supplementary Appendix 1.
The Pain Exposure Physical Therapy interven-
tion needed on the average 3.7 (SD 1.7) physical 
therapy treatment sessions (with two therapists) 
compared to 9.6 (SD 12.7) treatment sessions in 
the conventional treatment group. Besides the allo-
cated intervention the participants in the Pain 
Exposure Physical Therapy group had on the aver-
age 5.7 (SD 8.9) outpatient physical therapy con-
sultations, 2.9 (SD 3.0) general practitioner 
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consultations, 2.0 (SD 1.9) visits to medical spe-
cialists, and 0.4 (SD 1.2) consultations of the Pain 
Treatment Center at our University Hospital. 
Besides the allocated intervention, the participants 
in the conventional treatment group had on the 
average 6.2 (SD 5.0) outpatient physical therapy 
consultations, 3.3 (SD 3.6) general practitioner 
consultations, 2.2 (SD 2.0) visits to medical spe-
cialists, and 1.3 (SD 1.5) consultations at the Pain 
Treatment Center at our university hospital.
Cost-effectiveness planes are presented in 
Figure 2. The planes show that Pain Exposure 
Physical Therapy is cheaper and that there is a 
trend favoring this intervention for EQ-5D, and in 
particular Pain Disability, since point estimates are 
mainly located in the dominant quadrant of the 
cost-effectiveness planes (i.e. more effective and 
less costive).
Discussion
This economic analysis shows that Pain Exposure 
Physical Therapy is cost-effective as it saves costs 
when compared to conventional treatment in 
Figure 1. Patient flow.
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patients with complex regional pain syndrome type 
1. Patients in the group receiving the new therapy 
made fewer visits to see healthcare professionals. 
Similar to the findings of the effectiveness study, in 
which we found no significant clinical effects, there 
was no significant difference in health-related qual-
ity of life between groups.1 Calculated according to 
the intention-to-treat principle, Pain Exposure 
Physical Therapy was on average €1088 less costly 
than conventional treatment.
The strengths of the study are its randomized 
prospective design, the relatively long follow-up 
period (i.e. 9 months), blinded collection of cost 
data21 and the fact that this is the first trial compar-
ing Pain Exposure Physical Therapy to conven-
tional treatment in complex regional pain syndrome 
type 1. The number of patients switching between 
groups and the lack of data on productivity losses 
are limitations of this study.
Directly after randomization but prior to treat-
ment initiation, 14 patients deviated from the trial 
protocol and received a different treatment than to 
which they were assigned. The exact reason why 
this happened is unknown, but it stresses the impor-
tance of a thorough and careful explanation of what 
patients might expect when they participate in a 
randomized controlled trial.1 Perhaps, this is par-
ticularly important in patients who suffer from a 
debilitating and very painful condition such as com-
plex regional pain syndrome type 1. As a result, the 
primary intention-to-treat analysis was based on 
mixed groups and this may have yielded a conserv-
ative effect estimate. Further, not all patients who 
were allocated to the intervention group and 
received Pain Exposure Physical Therapy adhered 
to the treatment protocol. Nine patients received 
some form of medication or other conventional 
treatment. Most of this treatment was prescribed by 
their general practitioners, who were not involved 
in the trial. It was often not clear whether this medi-
cation was primarily related to complex regional 
pain syndrome type 1, but it could have had an 
Table 1. Descriptive data of the outcome measures.
Variable Baseline 3 months 6 months 9 months
EQ-5D index (maximum 1)a
 PEPT (n = 28) 0.53 (0.26) 0.63 (0.22) 0.77 (0.19) 0.76 (0.20)
 CONV (n = 28) 0.47 (0.29) 0.64 (0.26) 0.67 (0.32) 0.74 (0.25)
EQ-5D: EuroQol-5D; PEPT: Pain Exposure Physical Therapy; CONV: conventional treatment.
Data are mean (SD).
aAn increase means improvement.
Table 2. Cost data for different cost categories.
Pain Exposure Physical Therapy Conventional treatment
 Mean costs, € (SD) Mean costs, € (SD)
Consultations Pain Treatment Center 14 (40) 42 (48)
Inpatient Physical Therapy 605 (361) 874 (704)
Outpatient Physical Therapy 281 (424) 423 (705)
General Practitioner 41 (57) 40 (64)
Other consultations 472 (631) 573 (647)
Medication costs 131 (391) 100 (163)
Travel expenses 104 (67) 331 (403)
Total healthcare-related costs 1543 (1434) 2051 (1475)
Total costs including travel expenses 1648 (1447) 2382 (1775)
SD: standard deviation.
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Figure 2. Cost-effectiveness planes.
ICER: Incremental Cost Effectiveness Ratio; ISS-RV: Impairment level Sum Score—Restricted Version; PDI: Pain Disability Index.
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effect on the patients’ complaints. That is why we 
included these costs in the analyses.
Regarding generalizability, the conventional 
treatment adhered to the Dutch national guideline, 
and although this guideline was based on interna-
tionally published research articles,15 standard 
treatment may be different in other countries.
The difference in medication costs turned out to 
be smaller than anticipated, and even reversed in 
the intention-to-treat analysis probably due to the 
reasons described above. The difference in travel 
expenses is due to fewer consultations, both with 
the physical therapist and the anesthesiologist, in 
the Pain Exposure Physical Therapy group. The 
difference in physical therapy costs are relatively 
small, because in Pain Exposure Physical Therapy 
there are two physical therapists working together 
throughout each treatment session.
We initially intended to collect the cost data 
from the patients themselves. However, this turned 
out to be logistically unfeasible and resulted in data 
that were too incomplete. We therefore decided to 
collect the required information directly from the 
hospital administration system and from health 
insurance companies after informed consent of the 
patients involved. This allowed for reliable over-
views of the actual healthcare costs. Unfortunately, 
we did not receive the required information on 
healthcare costs from all the contacted health insur-
ance companies. That is why cost data were avail-
able for only 48 out of the 56 patients. These data 
were missing at random, because they did not cor-
relate with the measured value. Therefore, we did 
not impute missing data and we only used the data 
available for our cost-effectiveness analysis.
For the cost-analysis, we did not include costs 
caused by omission to work or productivity losses. 
Although we cannot make a substantiated statement, 
Pain Exposure Physical Therapy seems to be more 
relevant for society because of the shorter duration 
of treatment and perhaps quicker return to work.
As mentioned before, this is the first trial study-
ing the effects and cost-effectiveness of Pain 
Exposure Physical Therapy in patients with com-
plex regional pain syndrome type 1. The Cochrane 
systematic review on physical therapy in patients 
with complex regional pain syndrome type 1 found 
18 randomized trial studying a variety of physical 
therapy interventions such as electrotherapy modal-
ities (ultrasound, transcutaneous electrical neuro-
stimulation (TENS), laser, interferential therapy, 
and pulsed electromagnetic field therapy), both 
supervised and non-supervised exercise (active, 
active-assisted, passive, stretching, strengthening, 
mobilizing, and functional), manual lymphatic 
drainage, pain management advice, and sensory-
motor rehabilitation strategies (graded motor 
imagery, mirror therapy, virtual body swapping, 
and tactile sensory discrimination training).23  
About 15 of the 18 trials had high risk of bias. There 
was very-low-quality evidence suggesting that cor-
tically oriented grade motor imagery and mirror 
therapy might be useful to improve pain and disa-
bility.23 None of the trials studied Pain Exposure 
Physical Therapy, and only one study investigated 
cost-effectiveness and found that physical therapy 
was cost-effective compared to occupational ther-
apy and usual care.11,23
In conclusion, we can state the analysis of our 
trial was hampered by the proportion of patients 
who switched groups prior to treatment initiation 
and the lack of data on productivity losses. Despite 
that, the results are in line with previously reported 
positive studies on this intervention by our 
group.9,10 The differences in costs are in favor of 
the intervention group. Pain Exposure Physical 
Therapy can be considered a promising treatment 
for complex regional pain syndrome type 1, but its 
(cost)effectiveness needs to be further explored in 
sufficiently powered and methodologically sound 
randomized controlled trials.
Clinical Messages
•• Pain exposure physical therapy is less 
costly than conventional guideline-based 
care while reaching the same benefits in 
patients suffering from complex regional 
pain syndrome type 1.
•• These benefits can be achieved by a maxi-
mum of five physiotherapy sessions (pro-
vided by two physiotherapists) using the 
Pain Exposure Physical Therapy approach.
798 Clinical Rehabilitation 32(6)
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest 
with respect to the research, authorship, and/or publica-
tion of this article.
Funding
The author(s) disclosed receipt of the following financial 
support for the research, authorship, and/or publication 
of this article: The Netherlands Organization for Health 
Research and Development (ZonMw; 1709901004) 
funded this study. The funder had no role in the study 
design, data collection, data analysis, data interpretation, 
or writing of the report.
Supplementary Material
Because participants gave informed consent specifically 
for this study, and the final data set is only available for 
reuse after informed consent of the participants.
ORCID iD
J Bart Staal  https://orcid.org/0000-0002-0083-6380
References
 1. Barnhoorn KJ, van de Meent H, van Dongen RTM, et al. Pain 
exposure physical therapy (PEPT) compared to conven-
tional treatment in complex regional pain syndrome type 1: 
a randomised controlled trial. BMJ Open 2015; 5: e008283.
 2. De Rooij AM, Perez RS, Huygen FJ, et al. Spontaneous 
onset of complex regional pain syndrome. Eur J Pain 
2010; 14(5): 510–513.
 3. Bruehl S, Harden RN, Galer BS, et al. External valida-
tion of IASP diagnostic criteria for Complex Regional 
Pain Syndrome and proposed research diagnostic crite-
ria. International Association for the Study of Pain. Pain 
1999; 81: 147–154.
 4. Vlaeyen JW and Linton SJ. Fear-avoidance and its conse-
quences in chronic musculoskeletal pain: a state of the art. 
Pain 2000; 85(3): 317–332.
 5. De Jong JR, Vlaeyen JW, de Gelder JM, et al. Pain-related 
fear, perceived harmfulness of activities, and functional 
limitations in complex regional pain syndrome type I. J 
Pain 2011; 12(12): 1209–1218.
 6. O’Connell NE, Wand BM, McAuley J, et al. Interventions 
for treating pain and disability in adults with complex 
regional pain syndrome. Cochrane Database Syst Rev 
2013; 4: CD009416.
 7. Dworkin RH, O’Connor AB, Kent J, et al. Interventional 
management of neuropathic pain: NeuPSIG recommenda-
tions. Pain 2013; 154: 2249–2261.
 8. Barnhoorn KJ, Oostendorp RA, van Dongen RT, et al. 
The effectiveness and cost evaluation of pain exposure 
physical therapy and conventional therapy in patients 
with complex regional pain syndrome type 1. Rationale 
and design of a randomized controlled trial. BMC 
Musculoskelet Disord 2012; 13: 58.
 9. Ek JW, van Gijn JC, Samwel H, et al. Pain exposure 
physical therapy may be a safe and effective treatment for 
longstanding complex regional pain syndrome type 1: a 
case series. Clin Rehabil 2009; 23: 1059–1066.
 10. Van de Meent H, Oerlemans M, Bruggeman A, et al. 
Safety of “pain exposure” physical therapy in patients with 
complex regional pain syndrome type 1. Pain 2011; 152: 
1431–1438.
 11. Severens JL, Oerlemans HM, Weegels AJ, et al. Cost-
effectiveness analysis of adjuvant physical or occupational 
therapy for patients with reflex sympathetic dystrophy. 
Arch Phys Med Rehabil 1999; 80(9): 1038–1043.
 12. Van Dieten HE, Perez RS, van Tulder MW, et al. Cost 
effectiveness and cost utility of acetylcysteine versus 
dimethyl sulfoxide for reflex sympathetic dystrophy. 
Pharmacoeconomics 2003; 21(2): 139–148.
 13. Harden RN, Bruehl S, Stanton-Hicks M, et al. Proposed 
new diagnostic criteria for complex regional pain syn-
drome. Pain Med 2007; 8: 326–331.
 14. Husereau D, Drummond M, Petrou S, et al. Consolidated 
Health Economic Evaluation Reporting Standards 
(CHEERS)—explanation and elaboration: a report of 
the ISPOR Health Economic Evaluation Publication 
Guidelines Good Reporting Practices Task Force. Value 
Health 2013; 16: 231–250.
 15. Perez RS, Zollinger PE, Dijkstra PU, et al.; CRPS I Task 
Force. Evidence based guidelines for complex regional 
pain syndrome type 1. BMC Neurol 2010; 10: 20.
 16. Hakkaart-van Roijen L, Tan SS and Bouwmans CAM. 
Dutch guideline for costing research. Healthcare Insurance 
Executive Council, Diemen, The Netherlands, 2010.
 17. Janssen MF, Pickard AS, Golicki D, et al. Measurement 
properties of the EQ-5D-5L compared to the EQ-5D-3L 
across eight patient groups: a multi-country study. Qual 
Life Res 2013; 22: 1717–1727.
 18. Dolan P. Modeling valuations for EuroQol health states. 
Med Care 1997; 35: 1095–1108.
 19. Lamers LM, McDonnell J, Stalmeier PFM, et al. The 
Dutch tariff: results and arguments for an effective design 
for national EQ-5D valuation studies. Health Econ 2006; 
15(10): 1121–1132.
 20. Anderson P and Philips C. What is a Qaly? Available at: 
www.whatisseries.co.uk/what-is-a-qaly? (accessed 30 
January 2018).
 21. Oerlemans HM, Goris RJ and Oostendorp RA. 
Impairment level sumscore in reflex sympathetic dys-
trophy of one upper extremity. Arch Phys Med Rehabil 
1998; 79: 979–990.
 22. Soer R, Koke AJ, Vroomen PC, et al. Extensive valida-
tion of the pain disability index in 3 groups of patients 
with musculoskeletal pain. Spine 2013; 38: E562–
E568.
 23. Smart KM, Wand BM and O’Connell NE. Physiotherapy 
for pain and disability in adults with complex regional 
pain syndrome (CRPS) types I and II. Cochrane Database 
Syst Rev 2016; 2: CD010853.
